151 related articles for article (PubMed ID: 38530491)
1. Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA.
Yamamoto T; Kasahara M; Ueshima K; Uemura S; Kashihara N; Kimura K; Konta T; Shoji T; Mima A; Mukoyama M; Saito Y
Clin Exp Nephrol; 2024 Mar; ():. PubMed ID: 38530491
[TBL] [Abstract][Full Text] [Related]
2. Intensive uric acid-lowering therapy in CKD patients: the protocol for a randomized controlled trial.
Kasahara M; Kuwabara Y; Moriyama T; Tanabe K; Satoh-Asahara N; Katsuya T; Hiramitsu S; Shimada H; Sato T; Saito Y; Nakagawa T
Clin Exp Nephrol; 2020 Mar; 24(3):235-241. PubMed ID: 31729647
[TBL] [Abstract][Full Text] [Related]
3. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
Wada T; Hosoya T; Honda D; Sakamoto R; Narita K; Sasaki T; Okui D; Kimura K
Clin Exp Nephrol; 2018 Aug; 22(4):860-870. PubMed ID: 29372470
[TBL] [Abstract][Full Text] [Related]
4. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
Tsukamoto S; Okami N; Yamada T; Azushima K; Yamaji T; Kinguchi S; Uneda K; Kanaoka T; Wakui H; Tamura K
Clin Rheumatol; 2022 Mar; 41(3):911-919. PubMed ID: 34642880
[TBL] [Abstract][Full Text] [Related]
5. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
[TBL] [Abstract][Full Text] [Related]
6. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
[TBL] [Abstract][Full Text] [Related]
7. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
[TBL] [Abstract][Full Text] [Related]
8. Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report.
Tanaka A; Nakamura T; Sato E; Node K
Drugs R D; 2017 Mar; 17(1):97-101. PubMed ID: 28074335
[TBL] [Abstract][Full Text] [Related]
9. The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial.
Kuwabara Y; Yasuno S; Kasahara M; Ueshima K; Nakao K
Clin Exp Nephrol; 2020 May; 24(5):420-426. PubMed ID: 31875936
[TBL] [Abstract][Full Text] [Related]
10. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
[TBL] [Abstract][Full Text] [Related]
11. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
Stack AG; Dronamraju N; Parkinson J; Johansson S; Johnsson E; Erlandsson F; Terkeltaub R
Am J Kidney Dis; 2021 Apr; 77(4):481-489. PubMed ID: 33130235
[TBL] [Abstract][Full Text] [Related]
12. Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
Sezai A; Obata K; Abe K; Kanno S; Sekino H
Circ J; 2017 Oct; 81(11):1707-1712. PubMed ID: 28603225
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.
Matsuo H; Ishikawa E; Machida H; Mizutani Y; Tanoue A; Ohnishi T; Murata T; Okamoto S; Ogura T; Nishimura Y; Ito H; Yasutomi M; Katayama K; Nomura S; Ito M
Clin Exp Nephrol; 2020 Apr; 24(4):307-313. PubMed ID: 31845065
[TBL] [Abstract][Full Text] [Related]
14. Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis.
Luo Y; Song Q; Li J; Fu S; Yu W; Shao X; Li J; Huang Y; Chen J; Tang Y
BMC Nephrol; 2024 Feb; 25(1):63. PubMed ID: 38395818
[TBL] [Abstract][Full Text] [Related]
15. Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review.
Tsai CW; Lin SY; Kuo CC; Huang CC
PLoS One; 2017; 12(1):e0170393. PubMed ID: 28107415
[TBL] [Abstract][Full Text] [Related]
16. Uric Acid Lowering and Biomarkers of Kidney Damage in CKD Stage 3: A Post Hoc Analysis of a Randomized Clinical Trial.
Perrenoud L; Kruse NT; Andrews E; You Z; Chonchol M; Wu C; Ten Eyck P; Zepeda-Orozco D; Jalal D
Kidney Med; 2020; 2(2):155-161. PubMed ID: 32964203
[TBL] [Abstract][Full Text] [Related]
17. Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan.
Wang S; Shu Z; Tao Q; Yu C; Zhan S; Li L
Nephrology (Carlton); 2011 Nov; 16(8):767-76. PubMed ID: 21854506
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy for hyperuricemia in hypertensive patients.
Gois PHF; Souza ERM
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD008652. PubMed ID: 28406263
[TBL] [Abstract][Full Text] [Related]
19. Does uric acid-lowering treatment slow the progression of chronic kidney disease? A meta-analysis of randomized controlled trials.
Bignardi PR; Ido DH; Garcia FAL; Braga LM; Delfino VDA
Nefrologia (Engl Ed); 2023; 43(2):167-181. PubMed ID: 36564223
[TBL] [Abstract][Full Text] [Related]
20. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
